The authors used the PatchXpress ® 7000A system to measure compound activity at the hERG channel using procedures that mimicked the "gold-standard" conventional whole-cell patch clamp. A set of 70 compounds, including hERG antagonists with potencies spanning 3 orders of magnitude, were tested on hERG302-HEK cells using protocols aimed at either identifying compound activity at a single concentration or obtaining compound potency from a cumulative concentration dependence paradigm. After exposure to compounds and subsequent washout of the wells to determine reversibility of the block, blockade by a reference compound served as a quality control. Electrical parameters and voltage dependence were similar to those obtained using a conventional whole-cell patch clamp. Rank order of compound potency was also comparable to that determined by conventional methods. One exception was flunarizine, a particularly lipophilic compound. The PatchXpress ® accurately identified the activity of 29 moderately potent antagonists, which only weakly displace radiolabeled astemizole and are false negatives in the binding assay. Finally, no false hits were observed from a collection of relatively inactive compounds. High-quality data acquisition by PatchXpress ® should help accelerate secondary screening for ion channel modulators and the drug discovery process. (Journal of Biomolecular Screening 2005:168-181) 
INTRODUCTION
I ON CHANNELS ARE INTEGRAL MEMBRANE PROTEINS that support the passive flux of ions across cell membranes upon opening of an integral pore region by relevant stimuli (e.g., depolarization of the membrane potential during an action potential). With some exceptions, the ionic current flowing through a population of channels is a direct readout of the number of active channels mediating the current and the temporal profile of their probability of opening. Thus, the voltage clamp method, particularly the whole-cell configuration of the patch clamp technique, is the recognized gold standard for measuring the activity of populations of ion channels expressed in the plasma membrane of cells. 1 Currently, the conventional whole-cell patch clamp assay is the most reliable method available to accurately determine the activity of compounds at the human ether-a-go-go-related gene potassium channel (hERG). 2 hERG is the pore-forming subunit responsible for I Kr , a major current contributing to repolarization of the cardiac myocyte action potential. 3 The importance of identifying compounds with the potential to cause cardiac toxicity is underscored by the withdrawal of numerous therapeutic agents from the market due to drug-induced long QT syndrome and sudden death. [4] [5] [6] Unfortunately, the intense time commitment required to perform conventional recordings severely limits the determination of hERG activity to no more than 2 to 3 compounds per electrophysiologist per day. Recently, a voltage clamp device that uses planar electrode biochips from AVIVA Biosciences (SealChip 16 ™ ) was introduced by Axon Instruments (PatchXpress 7000A) to automate the conventional method. The PatchXpress ® enables continuous wholecell current recording from single cells during compound addition and washout, as well as diverse voltage protocols to be incorporated into the same experiment. This device is capable of independently recording in parallel from each of 16 wells in the custom-fabricated SealChip 16 ™ . Each well bears a single pore extending from the top extracellular chamber to a lower chamber filled with intracellular solution, which takes the place of the conventional patch electrode tip. In the present study, the PatchXpress ® instrument was tested for its ability to accurately 1) determine the IC 50 and rank order of potency for 8 compounds, 2) identify moderately potent hERG antagonists with IC 50 ≤ 3 µM (determined in the conventional electrophysiological assay) but are missed when tested in standard binding assays at 10 µM, and 3) identify compounds that are inactive in the conventional assay. Some of this work was presented previously. 7 
MATERIALS AND METHODS

Solutions and compound handling
Extracellular solution (hERG-ES) contained (in mM): 150 NaCl, 4 KCl, 1.8 CaCl 2 , 1 MgCl 2 , 5 dextrose, 10 hemi-NaHEPES (pH 7.4, and 320 to 330 mOsmolar). Intracellular solution (hERG-IS) contained (in mM): 120 KCl, 2 Mg-adenosine triphosphate (ATP), 0.5 CaCl 2 , 2 MgCl 2 , 10 HEPES, 5 EGTA free acid (pH 7.3 with KOH, and 310 to 320 mOsmolar) and was either made fresh or kept frozen until use to avoid degradation of ATP. Extracellular and intracellular solutions were sterile filtered prior to use. Compounds were made fresh from DMSO stocks (1000×) by adding the appropriate volume to the bottom of a 15-mL polypropylene tube and diluting with hERG-ES while vortexing. For these studies, some compounds (pimozide, astemizole, flunarizine, oxatomide) were sonicated at least 20 min prior to making solutions and also after the final solutions were prepared. Compounds were transferred to a 96-well polypropylene compound plate (Greiner #650261). Compound plates for the single concentration screen contained vehicle and compounds in the following configuration: DMSO (0.1%) (row A of the compound plate), compound at 10 µM (row B of the compound plate), and reference compounds (11 nM and 220 nM astemizole) that served as a quality control (QC) (rows C and D, respectively, of the compound plate). Twenty-nine proprietary compounds that inhibit I hERG ≥45% when applied at 3 µM (data not shown) and are inactive when tested at 10 µM in an in-house astemizole binding assay ( 3 H-astemizole binding blocked by <50%) were chosen to determine the false-negative rate. Most of these compounds were also tested at higher concentrations in the binding assay and exhibited IC 50 values of 30 µM. Inactive compounds used to determine the false-positive rate revealed <20% inhibition of hERG tail current when applied at 10 µM in conventional studies. Compound plates for 3-or 4-point concentration dependence experiments had a similar layout (i.e., DMSO, compound, QC), except that the compound was present in rows B, C, and D (and E in 4-point experiments) at increasing concentrations usually in half-log or log intervals starting at 1 or 3 nM for the most potent compounds and 10 or 30 nM for the least potent compounds. The components of the buffers were purchased from Sigma Aldrich Company (St. Louis, Missouri). Flunarizine and pimozide were purchased from Sigma. Dofetilide was purchased from Pfizer (New York, New York). Mibefradil was purchased from Hoffmann-LaRoche (Nutley, New Jersey) or purified from tablets. Remaining compounds used in this study were obtained from the proprietary corporate compound library.
Cell preparation
A significant difference between conventional and planar electrophysiological methods involves the handling of the cells prior to testing. HEK293 cells stably expressing recombinant human hERG channels (hERG302-HEK; obtained from Zhou 8 ) were harvested to obtain a suspension of cells that were >95% singlets just prior to testing on the PatchXpress ® . This is in contrast to the conventional method, in which cells were plated on poly-Llysine-coated Petri dishes or glass coverslips and allowed to adhere to the substrate for at least 6 to 12 h before testing. Cells were split into T75 flasks at a ratio of 1:3 or 1:4 and, on the day of testing (2 or 3 d later, respectively), had attained a confluency of 40% to 75%. hERG302-HEK cells from 3 frozen stocks were used in these studies and grown and handled in fetal bovine serum from either Hyclone (#SH30070.03) or GIBCO (#16000-044). The data obtained from these separate cultures were not significantly different and were combined.
Cells were harvested using solutions at room temperature. Cells were incubated in Versene (10 mL; Invitrogen GIBCO #15040-066) for 10 to 12 min followed by trypsin-EDTA 0.05% (5 mL; GIBCO #25300-054) until~50% of the cells were observed as singlets after gentle agitation of the flask (~15 min). The medium used to prepare the cells was similar to that used to culture the cells, except that it lacked antibiotics and was filtered and stored as 50-mL aliquots at 4°C prior to use. Medium (8 mL) was added to the flask to inactivate the trypsin, and the cells were gently triturated. Cells were transferred to a 15-mL screw-cap tube and centrifuged at 1000 rpm (140 g) for 15 s. The cell pellet was slightly agitated, and the supernatant (containing~0.5 million cells/mL) was incubated at 37°C with 5% CO 2 for 35 to 50 min. Cells were subsequently gently triturated using a transfer pipette and centrifuged for 30 s at 140 g. The pellet was gently resuspended in 150 µL sterile-filtered hERG-ES and tested on the PatchXpress ® within 5 min.
PatchXpress ® procedures
After manually placing the AVIVA Biosciences SealChip 16 ™ electrode arrays (purchased from Axon Instruments, Union City, CA) in the holder of the PatchXpress ® , the SealChip 16 ™ was automatically prepared for application of the cells. Intracellular solution was injected into the bottom of each chamber, and extracellular solution was perfused into the top of the chambers through the 16-nozzle wash station. Throughout this period, the pressure controller maintained a positive pressure (+10 mmHg) from the intracellular side to keep the hole free of debris. Cells were triturated by the integrated Cavro pipetting robot prior to addition of 5 µL (containing 10K-30K cells) to each well. After PatchXpress® hERG Assay 20 s, the pressure was switched to -30 mmHg to attract suspended cells to each of the 16 holes (electrodes). Seal formation was achieved by a ramp increase in negative pressure from -10 to -32 mmHg at a rate of 1.6 mmHg/s every 25 s until a GOhm (10 9 Ohm) seal was obtained and verified for 30 s. Whole-cell access was achieved by rupturing the patch of membrane over the hole using a ramp increase in negative pressure from 0 to -130 mmHg at a rate of 1.44 mmHg/s with a pipette potential of -80 mV. The cell was allowed to stabilize for 2 min, during which the access resistance (R a ) was monitored and improved, if necessary, by pneumatic feedback, and the experimental procedures were initiated. The R a optimization protocol was initially applied, which consisted of 1-s periods containing 7 square pulses to -70 mmHg every 5 s but was deactivated during data acquisition. From the time of whole-cell break-in to the end of the experiment, the cells were held at -80 mV between voltage protocols. Initially, the voltage dependence of activation of hERG was obtained using a family of voltage steps from -60 to +60 mV in 20-mV increments (1.5-or 2-s duration), followed by a test pulse to -40 mV (6 s) to elicit deactivating tail currents. The voltage dependence of activation was again determined after exposure to the highest concentration of compound. After optimizing R a and acquiring the initial current-voltage relationship, cells were challenged every 15 s with a voltage protocol that activated and inactivated the entire population of hERG channels (+60 mV for 2 s), followed by repolarization to open the channels and elicit a robust tail current (-40 mV for 6 s). The tail currents were monitored for rundown over 5 min, during which vehicle was administered (0.1% DMSO; see above for compound plate layout). The vehicle itself had no effect on hERG currents per se. Although there was cell-to-cell variability in the rate of rundown in these experiments, tail current amplitude decreased by only 1.2% ± 0.2% per minute (n = 93) (mean ± standard error of the mean, S x ) during the first 5 min of recording when rundown is greatest. Compound solution (40 µL) was added online (200 µL/ sec) at the desired concentration after aspiration of~90% of the buffer from the well. The compound solution was applied 3 times to each cell to fully exchange the solution in the well (this protocol diluted the solution in the compound plate by only~0.1%). The interval between additions of the same concentration of compound to a well was~60 s. Currents were monitored continuously during the 9-min exposure to the compound. Small +20-mV voltage steps to -60mV were applied at the beginning of each sweep to continuously assess membrane properties (membrane resistance, R m ). Because it was determined that cells could be insensitive to even the most potent blockers (e.g., pimozide) without any obvious electrophysiological hallmark (i.e., the cells had good R m and R a values and typical tail currents; see Results section), a QC reference compound addition was employed to flag cells whose hERG tail current was insensitive to the reference compound. After washout of the test compound, the reference compound astemizole was applied at its IC 50 concentration (11 nM; unpublished results), and data were accepted if the current was blocked by ≥25% (i.e., the QC criterion for acceptance), followed by near complete block by 220 nM astemizole. The blockade achieved by 11 nM astemizole was 55% ± 10% (n = 4) when tested using conventional methods using PatchXpress ® solutions. It should be noted that a subsequent series of studies at the Johnson & Johnson Pharmaceutical Research & Development site in Beerse, Belgium, revealed an astemizole IC 50 value of 4.4 ± 0.3 nM (n = 22; mean ± S x ). It is possible that the cell line at La Jolla (originally obtained from the Beerse site) and used for all PatchXpress ® experiments has diverged with regard to its sensitivity to certain compounds, including astemizole, or that differences in method (see below) account for some intersite discrepancies.
Two separate procedures were used to determine potency: 1 designed as a screen (e.g., percent block by compound at 10 µM; Fig.  6 ), the other as a 3-or 4-point concentration-response (e.g., IC 50 ; Fig. 3 ). In the screening procedure, after the vehicle control challenge, compound (10 µM) was applied to successful cells. Current-voltage relationships were acquired as described above, followed by a 3-min washout of compound and QC block by the reference compound. Six compounds were included in duplicate on each compound plate (columns 1 and 7, 2 and 8, etc.). Once data were obtained for a compound, the compound was not retested. The screening procedure involved continuous voltage clamping of the cells for about 35 min. In the 3-or 4-point concentration dependence procedure, increasing concentrations of each compound (pimozide, astemizole, dofetilide, flunarizine, cisapride, oxatomide, mibefradil, and ketoconazole) were applied to successful wells in a cumulative concentration-response format. Four compounds were included on each compound plate. Compound 1 was present in columns 1, 5, and 9 of the 96-well compound plate; compound 2 in columns 2, 6, and 10; compound 3 in columns 3, 7, and 11; and compound 4 in columns 4, 8, and 12. The procedure instructed the Cavro pipetting robot to pick up solutions from a particular column and add them to an individual well. Because the SealChip 16 ™ has a 16-well format, columns 1 to 4 would have been used twice if all wells were acceptable with regard to achieving whole-cell status.
Data analysis
Six metrics were analyzed: seal resistance (R seal ), membrane resistance (R m ), whole-cell membrane capacitance (C m ), access resistance (R a ; the 32-KHz bandwidth enabled accurate measurement of the time constant R a C m ≥25 µs), holding current prior to the step to +60 mV, and tail current amplitude determined near its peak (~100 ms after the step to -40 mV). Cells were not analyzed if the R m was initially <200 MOhm. Generally, the average of 3 tail current measurements at the end of a 9-min incubation period was calculated and compared to initial control levels. The tail current amplitude was measured using DataXpress/pCLAMP9 (Axon Instruments). Linear leak subtraction was performed offline using leak currents elicited by a +20-mV step from -80mV at the beginning of each sweep. The leak current calculated by this method was equivalent to that remaining during the -40-mV test voltage after application of a high concentration of reference compound to cells with stable R m . The difference between the recorded tail current and baseline (leak current at -40 mV) was calculated (I hERG ) and used to determine the percentage block by compound versus control. The concentration required to inhibit 50% of the leaksubtracted tail current (IC 50 ) was determined by fitting the Hill equation to the compiled concentration-response data using Prism 3.02 software (GraphPad, San Diego, CA). For these compounds, maximum and minimum values were held constant at 100% and 0% block. The voltage to half-activate (V 0.5 ) the population of hERG channels was determined before and after inactive compound addition in the screening procedure (n = 67) by tail current analysis and fitting I hERG with a Boltzmann equation using Prism software. The degree of lipophilicity was calculated according to the method of Wildman and Crippen (sLogP). 9 Unless otherwise indicated, the data are presented as the mean ± S x .
Conventional electrophysiological studies
The conventional ruptured patch clamp method was performed at room temperature at 2 Johnson & Johnson Pharmaceutical Research & Development sites (Beerse, Belgium, and La Jolla, CA). Most of the experiments were performed at the Beerse site (IC 50 values for 8 reference compounds, Table 1 , and circles in Fig. 7 ). Follow-up experiments were performed in La Jolla using solutions and cells used for the PatchXpress ® (squares in Fig. 7 ).
Beerse protocol
The intracellular solution was similar to that used for the PatchXpress ® experiments, except that the Mg-ATP was 4 mM, the pH was 7.2, and the osmolarity of the solution was 260 to 270 mOsm. Current signals were amplified and digitized by an EPC-9 patch clamp amplifier, stored, and analyzed with Pulse/Pulsefit software (HEKA), DataAccess (Bruxton), and Igor Pro (Wavemetrics). 10 In all experiments, 87% to 90% series resistance compensation was achieved. After establishing the whole-cell configuration and waiting 5 min for equilibration, the stimulation protocol was continuously applied (identical double-step protocol as that described above) every 15 s, and rundown was corrected. 10 Cells were continuously perfused by either control or drug-containing extracellular solution. The effect of compound was evaluated after 5 min of drug application. One to 3 concentrations of the drug were tested per cell (applied cumulatively in the case of multiple concentrations). Compounds were handled in glass vials.
La Jolla protocol
Similar experiments were performed to test the activity of a small set of compounds exhibiting unexpected results using an Axopatch 1D patch clamp amplifier (Axon Instruments), with a DigiData 1200B laboratory interface (Axon Instruments) using pCLAMP8 software. 11 Compounds were handled as described above for the PatchXpress ® experiments. Compounds were ap-plied at their final concentration in 5 times the chamber volume. The voltage protocols were identical to the PatchXpress ® protocols. The effect of compound was evaluated for 5 min or until steady-state inhibition was reached. Concentration dependence was analyzed using Prism software.
RESULTS
We investigated whether the automated 16-channel planar patch clamp PatchXpress ® 7000A could accurately measure ion channel activity and identify modulators in a manner comparable to a conventional whole-cell patch clamp. The hERG assay developed on the PatchXpress ® met 2 acceptance criteria prior to embarking on the study described here. The 1st criterion required that 4 reference compounds (astemizole, dofetilide, quinidine, and terfenadine), applied at their conventionally determined IC 50 values, inhibit hERG tail currents (I hERG ) by ≥25% (data not shown). The 2nd criterion required that the success rate for acceptable experiments per SealChip 16 ™ (see below) be ≥25%. All PatchXpress ® data reported in this study were obtained from 36 SealChip 16 ™ planar electrodes during a 13-d period. PatchXpress ® performance was evaluated and compared to a conventional whole-cell voltage clamp with regard to electrical parameters, voltage dependence of activation, compound rank order of potency, and false-positive and false-negative rates.
Whole-cell recording parameters (R seal , R m , and R a ) and success rates
The SealChip 16 ™ electrodes used in this study were from 5 separate lots. On average, 95.5% ± 1.2% of the 16 holes (n = 36 SealChips) had acceptable resistance (>1 MOhm and ≤2.8 MOhm). The resistance of each hole (electrode) on the 16-well SealChip 16 ™ was automatically measured prior to the addition of cells. The average acceptable electrode resistance was 1.7 ± 0.05 MOhm (mean ± S x ). The success rate to achieve a seal of at least 1 GOhm was 54% ± 3%, but in 31% ± 2% of the wells, the patch of membrane over the hole ruptured prematurely (prior to the seal re- sistance reaching 1 GOhm). The propensity for premature rupture of the patch into the whole well configuration depended on the protocol used for seal acquisition and the health of the cells. The time to achieve whole-cell access after addition of cells in these experiments was 193 ± 22 s (n = 261). Cells with an initial R m ≥200 MOhm in the whole-cell configuration were analyzed. The measured resistance is dependent on both membrane and seal resistances. We found that although hERG currents could be observed (albeit with decreased resolution) in recordings with large leak currents, there was a tendency for leaky cells to be less stable; thus, a membrane resistance of 200 MOhm was chosen as a cutoff. The average seal resistance (R seal ) of this cell population was 1.9 ± 0.1 GOhm (n = 286; Table 1) .
A "successful recording," defined as a cell having R m ≥200 MOhm for at least 15 min, occurred in 48% of the 550 starting wells. The success rate for an "acceptable experiment" was 25% (140 cells) and required the cells to express hERG (4% of the "successful recordings" had no detectable hERG current), survive the lengthy procedures (~35-or~60-min duration), exhibit stable recordings, and pass the QC criterion (see below). The amplitude of the hERG tail current expressed in these cells was 970 ± 45 pA (n = 140). The membrane resistance (R m ) was 710 ± 40 MOhm (n = 140), and R a averaged 14 ± 1 MOhm (n = 132) ( Table 1) . No access resistance (R a ) optimization was applied during the recordings after the initial stabilization period. These values are comparable to those obtained in conventional recordings in which GOhm seals were obtained ( Table 1 ). The membrane capacitance (C m ) was 17.4 ± 1.3 pF (n = 133).
Voltage dependence of activation
A standard step protocol was used to determine the voltage dependence of activation of hERG using the PatchXpress ® (Fig. 1A) . The voltage to half-activate hERG (V 0.5 ; Fig. 1B ) was determined by tail current analysis and was initially -14 ± 1 mV (n = 67). There was no correlation between V 0.5 and R m in these experiments (data not shown). After about 20 min, a compound-independent leftward shift in the voltage dependence of activation was observed (V 0.5 was -23 ± 1 mV [n = 67] for the same cell population of cells). In conventional patch clamp experiments, V 0.5 was initially -16 ± 2 mV (n = 16). No shift in V 0.5 was detectable over 10 min in the presence of vehicle in conventional studies on a subpopulation of these cells (initial: -17 ± 2 mV vs. final: -18 ± 3 mV; n = 7).
IC 50 and compound rank order of potency: PatchXpress ® versus conventional methods
Accurate identification of compound rank order of potency across chemotypes on a pharmacologically relevant target is critical for the generation of meaningful structure-activity relationships. This is particularly important for targets modulated by a wide range of chemically and pharmacologically diverse entities, as is the case with hERG. 12 Therefore, the potencies of 8 chemically diverse drugs (pimozide, astemizole, dofetilide, cisapride, flunarizine, oxatomide, mibefradil, and ketoconazole) to block hERG were determined using PatchXpress ® and compared to those obtained using conventional methods.
The PatchXpress ® procedure included determination of initial rundown and the degree of stabilization of tail current amplitude prior to exposure to compounds at increasing concentrations using a cumulative paradigm. Cells were exposed to each concentration of compound for 9 min. Raw data traces revealing the inhibition of I hERG observed with dofetilide on the PatchXpress ® are shown in Figure 2 . Consecutive current sweeps elicited by the indicated voltage protocol before and after exposure to 0.1% DMSO vehicle (left), 10 nM dofetilide (center), and 100 nM dofetilide (right) are superimposed. Tail current was inhibited by 18% and 100% during exposure to 10 and 100 nM dofetilide, respectively. No rundown of I hERG was observed in this cell. There was little block of the outward current elicited by a step to +60 mV, consistent with the presence of only small hERG currents at voltages at which hERG channels exhibit rapid inactivation.
Online data analysis was used to display the tail current amplitude as the experiment progressed. An example of an entire 3-point concentration response experiment in which a cell was challenged with ketoconazole is shown in Figure 3 . During the acquisition of data using a current-voltage paradigm (indicated by the open arrow), tail currents increased and reached a plateau at voltage steps more positive than 0 mV (also see Fig. 1 ). After a short period during which membrane parameters were measured, I hERG measurements resumed as the cell was challenged with the voltage protocol indicated in Figure 2 . DMSO vehicle (0.1%) was applied to determine the initial degree of current rundown prior to the addition of ketoconazole. In this example, very little effect of ketoconazole was observed at 100 nM and 1 µM, but 10 µM blocked~70% of the tail current. After incubation in the highest concentration of compound, the voltage dependence of activation was again measured to determine whether decreases in current observed in the single-step voltage protocol could be accounted for by shifts along the voltage axis. The voltage dependence of activation in the presence of ketoconazole was similar to that initially observed. I hERG recovered when drug was subsequently washed out for 3 min. Astemizole applied at its IC 50 served as an internal quality control and blocked the tail currents by greater than 25% (criterion for acceptable sensitivity to reference compound). Finally, subsequent application of 220 nM astemizole completely and rapidly blocked I hERG . Experiments such as these were performed for each of the 8 hERG inhibitors, and the concentration dependence for each compound is shown in Figure 4 .
The negative log IC 50 values (pIC 50 ) obtained from the PatchXpress ® (gray bars) and conventional whole-cell recordings (solid bars) are plotted in Figure 5A . Error bars indicate the 95% confidence interval. In most cases, the pIC 50 values for the reference compounds obtained from the PatchXpress ® were not significantly different from those obtained using conventional methods; the 2 exceptions were dofetilide (more potent) and flunarizine (substantially less potent). Follow-up experiments were performed using conventional methods on acutely harvested and adherent (traditional cell preparation) hERG302-HEK cells. As there were no differences observed between acutely harvested cells and cells handled in the conventional manner for the compounds tested in this study, the data were combined. Dofetilide, applied at its reported IC 50 value, blocked 78% ± 4% (n = 3) of the current using conventional methods, comparable to 76% ± 19% (n = 26) observed using PatchXpress ® .
Further experiments were performed using flunarizine in an attempt to understand the factors contributing to the discrepancy (30-fold difference in potency) between methods. We determined whether a steady-state block had been reached in the PatchXpress ® experiments. In most cases, inhibition of I hERG reached steady state by 7 min (Fig. 5B ). Only flunarizine (solid diamond symbols) had not reached steady state at concentrations near or below its observed IC 50 at the time the next concentration was applied, contrib-uting in part to the discrepancy observed with conventional data. Nearly an order of magnitude of the difference was due to the handling of flunarizine (see Materials and Methods). In conventional studies using compound as it was prepared for the PatchXpress ® , the IC 50 was 250 nM (95% confidence interval: 135-460 nM, n = 3). Flunarizine is a highly lipophilic compound with a calculated logP (sLogP) of 5.48. In the experiments presented here, compounds were diluted in polypropylene tubes and 96-well plates. The IC 50 was only 2-fold rightward-shifted in single-addition protocols when glass was used to store compound solutions prior to running on the PatchXpress ® and then stored in glass-coated 96well plates during the experiments (data not shown). There appeared to be a tendency in these experiments for compounds with higher calculated logP to reveal larger discrepancies with data obtained using the conventional method (see below). The cell was challenged with a series of voltage steps from -60 to +60 mV in increments of 20 mV for 1.5 sec to activate hERG channels expressed on the plasma membrane. After 1.5 s at the indicated voltage, the voltage was stepped to -40 mV to determine the "tail current," the K + current through channels that had been opened or inactivated during the previous potential (arrowhead). The peak current elicited at -40 mV is a measure of the fraction of channels that were opened during each 1.5-s step. As observed in conventional whole-cell voltage clamp studies, outward hERG currents slowly activated during a voltage step to -40 mV. The largest outward current was observed during the 1.5-s step to 0 mV (indicated by the labeled arrow), and the current amplitude decreased when more positive voltage steps were applied due to rapid channel inactivation. The peak tail current elicited by the step to -40 mV was leak subtracted offline is plotted in (B) and used to determine the voltage to activate 50% of the channels, V 0.5 (-11.3 mV in the example shown). Tail current analysis reveals that voltage steps to +20 mV and above fully activate the channel population.
PatchXpress® hERG Assay
Identification of false negatives
Not all compounds that block hERG channels are identified in displacement assays employing ligands that bind to the intracellular vestibule of the channel pore. We determined whether the PatchXpress ® could identify compounds that significantly inhibit I hERG in conventional whole-cell patch clamp experiments but have little effect on astemizole binding (block <50%) when tested at 10 µM (data not shown). Twenty-nine proprietary compounds from 19 different chemical classes that blocked hERG currents by ≥45% when applied at 3 µM were tested at 10 µM on the PatchXpress ® using a screening procedure (see Materials and Methods). An example of the online results from a typical experiment is shown in Figure 6 . The procedure was identical to the concentration dependence procedure (above; Fig. 3) , with the exception that only a single concentration of compound was applied. In the example shown, the addition of DMSO vehicle caused an immediate decrease in current likely attributable to the loss of the contribution of a coupled cell (i.e., the capacitance of the cell decreased significantly from the initial value). The currents were stable prior to addition of compound (triplicate black arrows). Upon the 1st addition of compound, the tail current immediately decreased, with no detectable change in R m (as calculated from the steady-state current elicited by the small test pulse at the beginning of each sweep). The raw current traces before and after compound addition are shown to the right. The current rapidly decreased after addition (indicated by the transient current artifact). This compound blocked I hERG by 90% ± 1% (n = 5) and 98% ± 0.3% (n = 3) at 3 and 10 µM, respectively, in the conventional assay. The current-voltage relationship in the presence of compound revealed a decreased maximum current at all voltages (clear arrow). The current recovered quickly upon washout of the compound. Astemizole at its IC 50 blocked 50% of the current, and 220 nM astemizole rapidly and completely blocked I hERG .
The PatchXpress ® correctly identified all 29 compounds as antagonists when at least 50% inhibition of I hERG was used as the criterion for the identification of an inhibitor (Fig. 7A, solid symbols) . Overlaid on these PatchXpress ® data are data obtained using 10 µM compound in conventional experiments (clear symbols). On the whole, the performance of the PatchXpress ® was similar to the conventional method, especially for compounds with calculated logP <5. The compounds are sorted by their calculated logP values, from the least lipophilic (left) to the most lipophilic (right). The block by the compounds at the far right (high calculated logP values) tended to be underestimated by the PatchXpress ® . The compounds at the far left showed a tendency to block a higher proportion of channels than observed using the conventional method. Interestingly, the block by these compounds reached steady state very quickly in the PatchXpress ® assay, so this apparent difference cannot be attributed to the shorter incubation time employed in the conventional method.
Determination of the false-positive rate
No false hits were identified from a collection of 33 inactive compounds. The cells exposed to these compounds at 10 µM subsequently passed the QC and exhibited ≥25% block by the reference compound applied at its IC 50 value (Fig. 7B) . None of the compounds tested produced more than 35% inhibition of hERG tail current. A comparison of the percent block by these compounds (10 µM) on the PatchXpress ® (Fig. 7B, solid symbols) to their activity using conventional methods (Fig. 7B, clear symbols) revealed that the observed values were similar.
Experiment failures
Although 290 cells had initial R m values ≥200 MOhm, only 140 cells provided acceptable data on the compound block. Table 2 shows the outcome of each cell from each experiment. The most frequent experiment failures were due to 1) failure to pass the internal QC (23% of all unacceptable experiments: 17% from screening and 6% from concentration-response experiments), 2) loss of acceptable whole-cell parameters during the time required to determine the block by compound (19%: 15% concentration response, 4% screening), 3) loss of acceptable whole-cell parameters during the first 15 min (R m dropped significantly below 200 MOhm; 18%), and 4) long-lasting but reversible I hERG fluctuations that were often initiated by solution addition (16%: 7% concentration response, 9% screening).
There was no I hERG detectable (the limit of detection in successful recordings was~10 pA) in 8% of the failures. Five percent were lost during the addition of fluid via the Cavro pipetting robot. During the development of the assay, it was determined that the pharmacology was more accurate when compounds were added to the wells at the highest rate (200 µL/s). Additions at the highest rate appeared to dislodge cells that were not well sealed and cause reversible fluctuations in current associated with changes in resistance that recovered. Subsequent experiments indicated that appropriate pharmacology is achieved using slower speeds (data not shown). Very few cells (1% of failures) were lost during the washout procedure. Concentration-response experiments are indicated with italics ( Table 2) . The next series of measurements were taken before, during, and after a double DMSO 0.1% addition (indicated by the pairs of arrows). After a short 30-s period to measure R m , C m , and R a , cells were exposed to 0.1 µM ketoconazole (3 separate additions~60 s apart, as indicated by the 1st triplet set of arrows). The cell was subsequently challenged with 1 µM ketoconazole, followed by 10 µM ketoconazole for 9 min each, prior to determining the voltage dependence of activation (2nd clear arrow). Compound was washed out for 3 min, and the cell was subsequently challenged with astemizole as a quality control measure (gray arrows indicate the applications of the reference compound at its IC 50 ; gray arrowheads, at 20-fold its IC 50 ).
FIG. 4.
Concentration dependence of known hERG antagonists. Data were compiled from the number of successful cells indicated on each graph. Each graph shows the percent block of I hERG by the indicated concentrations of compound (pimozide, astemizole, dofetilide, cisapride, oxatomide, flunarizine, mibefradil, and ketoconazole). The IC 50 was determined from the block at each concentration and is expressed as a pIC 50 in Figure 5 . Error bars indicate the standard deviation. In a few cases, only single data points were obtained.
in concentration-response experiments compared to screening experiments are consistent with the differential length of the experiments.
Astemizole was chosen as the reference compound to QC the assay. Cells that were not successfully blocked by astemizole at the end of the experiment accounted for the highest percentage of failures (reason 1). The insensitivity to astemizole in a subpopulation of cells from the same cell preparation was observed early as well as late in the experimental procedure. Applying 11 nM astemizole as the test compound revealed sensitive and insensitive cells in the same experiment. The occurrence of QC failures appeared to be nonrandom. Table 2 reveals the variability among experiments and  the tendency for cells to be less sensitive to astemizole toward the  end of the study (Table 2 , "Failed QC" column). Although very few QC failures were observed in concentration-response experiments, many of the reference compounds used to determine rank order of potency were slowly reversible, and the complete block of I hERG in this cumulative paradigm prohibited QC testing. Inclusion of data on "irreversible" inhibitors applied to insensitive cells could contribute to rightward shifts in potency of some compounds (e.g., astemizole, Fig. 5A ).
No measured parameter consistently correlated with QC failure. Cells exhibiting excellent whole-cell recording parameters were observed to be insensitive to pimozide at concentrations less than 1 µM as well as to astemizole at 11 nM. As a group, cells failing the QC had R m of 725 ± 62 MOhm (n = 34) during exposure to 11 nM astemizole, a value similar to their initial R m (770 ± 70 MOhm, n = 34). Furthermore, there was no correlation of the decreased sensitivity of cells with any of the other parameters monitored (including C m , time to seal, time to achieve whole cell, and R a ). hERG channels expressed in cells that failed the QC could initially be inhibited by reversible antagonists (e.g., cisapride and proprietary compounds). In 1 case, after 100 nM cisapride blocked 43% of the current (a value within the range obtained from acceptable cells), rinsing with compound-free solution nearly fully reversed the inhibition, and subsequent addition of 11 nM astemizole had no effect on I hERG . The R m of this cell (625 MOhm) was stable throughout the experiment.
In preparations in which a large proportion of failures were due to QC failure, as many wells passed the QC criterion as in experiments having no incidences of QC failure (e.g., SealChip 29, 30, and 36). A notable difference between conventional and PatchXpress ® methods is the ability to select the cell for study under visual inspection; therefore, it is not surprising that the overall cell quality influences the quality of the assay.
DISCUSSION
We report for the 1st time a detailed comparison of data generated by the PatchXpress ® 7000A automated parallel patch clamp system using 16-well planar SealChip 16 ™ electrodes and the conventional gold-standard method of a whole-cell voltage clamp. We show that the PatchXpress ® is comparable to the gold-standard method in its ability to accurately measure recombinant hERG channel activity and identify pharmacologically diverse inhibitors with potential cardiac liabilities.
The PatchXpress ® accurately rank ordered 7 of 8 reference compounds whose potencies spanned 3 orders of magnitude. The 1 observed discrepancy could be attributed to handling the compound in plastics and failing to reach the steady-state block within the time allotted for compound incubation. The PatchXpress ® identified the antagonists with IC 50 ≤3 µM that are missed in In the PatchXpress ® experiments, the number of cells that were challenged with a particular reference compound was random and depended on the timing of cell readiness to initiate the procedure and whether the experiment was successful. Significant differences between conventional and PatchXpress ® data are indicated with asterisks. (B) The time to achieve a steady-state block on the PatchXpress ® is plotted for each reference compound at the concentrations indicated. The time between the 1st addition of drug at the indicated concentration and the stabilization of tail currents was determined, and data were combined and averaged. The time at which the current stabilized was defined as the 1st data point that was within 1% of the current measured 45 to 60 s later. At all concentrations for which data could be obtained accurately, all compounds except flunarizine reached steady-state inhibition by about 7 min. The time decreased with increasing concentration of antagonist. The circled black diamond is an underestimate of the time required to achieve a steady-state block by 100 nM flunarizine. astemizole binding assays when tested at 10 µM. There were no false positives in a set of 33 inactive compounds. The voltage dependence of activation was not significantly different from that observed using conventional methods, with the possible exception that a slight leftward shift was observed after 20 min on the PatchXpress ® , whereas no significant shift was observed after 10 min using conventional equipment. Voltage dependence of activation measured on the PatchXpress ® was similar to reported values for recombinant hERG expressed in mammalian systems 13 (and the present study) and Xenopus oocytes. 14 Finally, the electrical parameters were similar to those achieved in conventional methods ( Table 1) . No R a optimization was applied during the course of these recordings, yet R a averaged 14 MOhm using SealChip 16 ™ , with hole resistances averaging 1.7 MOhm. The inclusion of the R a optimization feature might have enabled the maintenance of R a values within a specified range under 10 MOhm by applying flexible pressure control paradigms as needed between voltage protocols. We have recently exploited these features to achieve lower R a values (data not shown).
The PatchXpress ® enhanced throughput of data acquisition about 4-fold. In the time required to obtain data on a single com-pound using the conventional whole-cell patch clamp, an average of 4 successful experiments was achieved per 16-channel SealChip 16 ™ . Although 53% of the wells initially provided quality recordings as defined by R m ≥200 MOhm, the 2 experimental procedures described here were very stringent, often running 35 or 60 min in length. The procedures included an initial rundown assessment (a standard protocol in the conventional method as well), incubation in at least 1 concentration of compound, and a subsequent internal quality control procedure. For inhibitors whose effect could be reversed, the PatchXpress ® procedures enabled an internal comparison of compound activity to a known hERG antagonist, astemizole.
The ability of the PatchXpress ® to simultaneously apply compounds and record whole-cell currents enables kinetic measurements with millisecond time resolution. In the present study, moderately potent hERG antagonists exhibiting <50% inhibition of astemizole binding when applied at 10 µM could be observed to block hERG currents within a second (e.g., Fig. 6B ). The extremely fast kinetics of the block observed with compounds with low calculated logP values (predicted to have a low lipophilic character) suggest that these compounds may bind to an external site on Figure 3 , each point represents the peak tail current observed after a step to -40 mV elicited every 15 s throughout the experiment, with the exception of 30-s periods between compound additions or changes in voltage protocol (gaps). The cell was exposed initially to the vehicle (double arrows) and then test compound (triple arrows) for 9 min prior to determining the voltage dependence of hERG activation in the presence of compound. Compound was washed out for 3 min (upward arrow), and the cell was subsequently challenged with the quality control procedure (as described in the Fig. 3 legend) . (B) Unmodified current sweeps are shown before and after exposure to a hERG antagonist that was a poor displacer of astemizole binding when tested at 10 µM. The addition of compound caused an immediate decrease in tail current amplitude, without affecting the health of the cell, as indicated by the stability of the current step evoked by a 20-mV depolarizing voltage step at the beginning of the sweep (i.e., stable R m ).
the channel. Thus, the PatchXpress ® was able to provide information on the kinetics of compound block and recovery. The flexibility of the system allows numerous and diverse voltage protocols to be applied to a cell to investigate a compound's mechanism of action. The applicability of the PatchXpress ® to the study of ligandgated ion channels has also been realized (data not shown).
The hERG assay developed on the PatchXpress ® accurately rank ordered 7 of 8 compounds in terms of their potency to block hERG. The IC 50 values were comparable to those obtained by conventional methods, with the exception of flunarizine, which was significantly right-shifted. The observed discrepancy between the PatchXpress ® and the conventional whole-cell patch clamp appeared to depend on compound handling and the inability of flunarizine to reach the steady-state block, rather than instrument issues. Conventional methods using the solutions applied to the PatchXpress ® revealed a 6-fold right-shifted concentration dependence. Interestingly, there was a tendency for the inhibition of hERG by compounds with high calculated logP values (i.e., highly lipophilic) to be underestimated. The use of glass vials and glasscoated plates for compound handling largely mitigated this right-ward shift in potency values observed with flunarizine. Further improvements will be realized when compounds are allowed to reach a steady-state block by employing software features that would ensure that the currents are stabilized prior to initiating the next step of the procedure.
The PatchXpress ® assay differs from conventional methods in a number of significant respects, with the most notable being the preparation of the cells for whole-cell recording. In conventional studies, hERG302-HEK cells rarely fail the internal QC (unpublished results). The failures observed in the present study on the PatchXpress ® may be associated with the preparation of cells because this phenomenon appeared nonrandom. Although the mechanism underlying the inability of the reference compound to adequately block hERG currents is unknown, the integrity of the seal and cell membrane is an unlikely mechanism because the measured whole-cell "membrane" resistance R m (a combination of membrane and seal resistance) is not diminished in this population of cells. It is not known whether this parameter would contribute to reference compound sensitivity of hERG expressed in cells with R m <200 MOhm (the cutoff used in this study). The random selection of cells by the planar method (in contrast to the possibility for the selection of visually acceptable cells in a conventional patch clamp) likely contributes to the increased failure rate. Thus, passing an internal quality control was found to be essential in these planar patch clamp experiments and provided confidence in the quality of the data in experiments in which compounds were found to have little or no effect on hERG currents. We are currently investigating the possible reasons underlying the insensitivity to potent hERG antagonists of a significant fraction of cells in some acute cell culture preparations. Because a quarter of the failures were cells that completed the experiment but did not pass the QC criterion, acquiring acceptable compound data from these cells would provide a significant increase in throughput.
The mechanism underlying the leftward shift of V 0.5 over the course of the experiment is not known but may include modulation of hERG by lysophospholipids and phosphatidylinositol-4,5bisphosphate and a gradual shift in Donnan equilibrium junction potential. [15] [16] [17] The shift observed in conventional patch clamp experiments is reported to be small, if any, and may relate to the differences in electrode configuration. The extent of cell perfusion and loss of diffusible intracellular components in the ruptured whole-cell patch clamp configuration may be similar to that observed in conventional methods, but the geometry of the pores in the proprietary SealChip 16 ™ has not been disclosed. Significant technological advances have been made in recent years by a number of companies to automate the gold-standard patch clamp technique for assaying ion channel function. [18] [19] [20] [21] [22] [23] The PatchXpress ® is a multiwell instrument that uses planar electrodes to enable the flexibility and high-quality data achievable in conventional patch clamping. This is, in part, due to the ability of the SealChip 16 ™ planar electrodes to form GOhm seals with cell membranes with high frequency. 23 High-quality whole-cell patch clamp data acquisition and handling have been enabled by a combination The activity of hERG blockers on PatchXpress ® was similar to their activity using a conventional whole-cell patch clamp. hERG antagonists with IC 50 values ≤3 µM that are missed when tested at 10 µM in an astemizole binding assay all blocked tail currents by ≥50% using PatchXpress ® (A), and no false hits were identified when a set of compounds inactive at 10 µM was tested (B). The compounds are ranked by their calculated logP value, with highest values (most lipophilic) to the right. Each symbol represents the percent block of a compound on a separate cell. The percent block for each compound was determined either on the PatchXpress ® (filled circles) or with conventional methods (clear symbols). Clear circles and squares represent the data acquired using a conventional whole-cell patch clamp at 2 independent Johnson & Johnson Pharmaceutical Research & Development sites (see Materials and Methods). Only compounds tested at 10 µM by both PatchXpress ® and the conventional method are shown. Dotted lines separate the compounds into bins based on their calculated logP (sLogP) values. The number above each dotted line indicates sLogP values delineating each bin; sLogP = 1.48 to 6.8 (A) and 0.9 to 6.16 (B). of the consistency of achieving high seal rates using the SealChip 16 ™ planar electrodes, the precision of the PatchXpress ® hardware, and the flexibility of the data acquisition and analysis software.
CONCLUSIONS
The hERG assay developed on the PatchXpress ® is a robust assay that accurately identified the activity of 69 of 70 compounds (98.6%) tested. The PatchXpress ® identified all antagonists tested in this study when quality control criteria were met and accurately identified compounds with little or no antagonist activity as inac-tive. The PatchXpress ® provided an increased throughput of at least 4-fold over conventional electrophysiology techniques, with the added benefit of improved consistency of experimental procedures among cells. The PatchXpress ® automated patch clamp provided high-quality data comparable to those obtained using the conventional gold-standard method.
